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Abstract
© 2017, Media Sphera. All rights reserved. Objective: To evaluate the long-term safety and
efficacy of intrajejunal levodopa-carbidopa intestinal gel (LCIG) infusion in the treatment of
patients with severe stages of  Parkinson disease (PD) who did not  respond adequately to
treatment with oral drugs. Material and methods: A large-scale international prospective open-
label 54-week study of LCIG in patients with PD with severe motor fluctuations was carried out.
A total of 48 patients were enrolled in Russia, 46 patients (95.8%) had PEG-J inserted, and 43 of
them completed the study. The safety, including adverse events (AEs), infusion system and
pump failures  analysis,  number  of  patients  completely  terminated the  study,  and efficacy
(duration of “off” periods, “on” periods with or without troublesome dyskinesias, UPDRS scores,
Clinical Global Impression, Quality of Life (PDQ-39, EQ-5D и EQ-VAS) dynamics, an analysis of
patient’s diaries) were assessed throughout the whole study. Results: The majority of AEs were
mild or moderate with most AEs connected with infusion system application (28.3% patients)
including procedure pain. Serious AEs were registered in 8 patients (16.7%). 3 patients (6.3%)
discontinued their participation in the study due to AEs. Mean duration of “off” periods by the
end of the study decreased by 5.35±2.59 hours (p < 0.001), duration of “on” periods without
troublesome dyskinesia increased by 5.74±3.91 hours (p < 0.001), reduction of “on” periods
duration with troublesome dyskinesia became statistically significant by week 36 (p=0.020). The
statistically significant improvement of UPDRS (generally and in respect to sub-scales), Clinical
Global Impression, and Quality of Life scores was observed throughout the study. Levodopa
dose remained stable throughout the 54 treatment weeks. Forty-three patients (93.5%) received
LCIG monotherapy throughout the whole study. Conclusion: LCIG intrajejunal infusion during 54
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